Health Condition 1: L309- Dermatitis, unspecified
Conditions
Interventions
Intervention1: Methotrexate delivery through Iontophoresis
: Iontophoresis using Methotrexate solution will be carried on study palm/ sole with injectable preparation of Methotrexate (50mg /2ml) once
Sponsors
SELF
Eligibility
Inclusion criteria
Inclusion criteria: Patients of age 18-60 years and consenting for the study. Patients having palmoplantar hyperkeratotic eczema predominantly, having lesions of duration more than 8 weeks.
Exclusion criteria
Exclusion criteria: Non consenting patient. Pregnant and lactating females Patient with hematological, renal, hepatic disorder and having malignancy. Patient those on pacemakers ,cardiac arrhythmias, metallic implanted devices in the area current flows or intrauterine metallic implantations . Hypersensitivity to previous methotrexate. Patient who are on other immunosuppresive agent. Patient who had been on systemic or topical steroids for >2 months. Patients of palmoplantar hyperkeratotic eczema with proven allergen will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Side effects both local and systemicTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Cure of the disease by HECSITimepoint: 3 MONTHS | — |
Countries
India
Contacts
Public ContactSuvigya Sachan
Kalinga Institute Of Medical Sciences
Outcome results
None listed